ATI Pharma

News & Events

Milestones

Summary of Product Development and Product Launch Activities

  1. April 1, 2011

    Sign Licensing agreement for platform technology with NUS

  2. March 2012

    Obtain Health Canada Approval for NutraPause

  3. July 2012

    Obtained Health Canada Approval for Amended claims for NutraPause

  4. August 2012

    Obtain Health Canada Review of Submission for Cardio Health Product

  5. January 2012 – June 2013

    Entered agreement with Johnson and Johnson (J&J) who performed all of the Quality Controls on the product and our selected packaging company in Singapore and manufacturer

  6. March 2013

    Incorporated USA Affiliate

  7. January – March 2013

    Signed a Shareholders Agreement with Keith Larson appointed as Director and President of USA affiliate

  8. June 2013

    Obtained Health Canada approval for OsteoProtect

  9. July 2013

    Entered into an Exclusive Distribution Agreement with TFB and Associated for Canada alone

  10. December 2013

    Signed contract manufacturing agreements

  11. January 2014

    TFB and Associates completes agreements with Safeway Canada and tentative agreements with Rexall and IDA/Guardian

  12. February / March 2026

    Planned Launch for NutraPause in Canada

  13. July 2026

    Planned online Launch for NutraPause in the USA

  14. September 2026

    Health Canada submission for Cardio-Plus

  15. January 2027

    Planned launch for OsteoProtect in Canada and USA

  16. April 2027

    Planned Launch for CardioPlus Product in Canada and USA

  17. September 2027

    Planned Launch for NutraPause in Europe